MEDTECH, AI
Quantum-Si | January 10, 2023
The leading Protein Sequencing Company™, Quantum-Si, recently announced that it signed a partnership and license agreement with Biovista to offer customers more significant proteomic insights beyond their protein sequence output.
Biovista utilizes artificial intelligence in multiple formats to analyze enormous data repositories and visualize non-obvious networks and connections between proteins, diseases, and drug mechanisms of action. The partnership enhances Quantium-Si's services significantly by making proteomic-to-drug workflows more efficient for researchers.
Biovista's VIZIT™ exploration tool will be incorporated into Quantum-Si's cloud-based suite of analytic tools, allowing researchers to visualize the connections between the protein sequences identified during their experiment to diseases, other proteins, and post-translational modifications. Thus, researchers can identify potential disease-specific mechanisms and biomarkers more efficiently and effectively.
"Quantum-Si's protein sequencing technology in concert with Biovista's database and visualization technology can aid in the discovery of new proteins for future therapeutic targets associated with disease," said Jeff Hawkins, CEO of Quantum-Si. He further stated, "The potential can also extend to discovering new biomarkers for clinical research and diagnostics."
(Source- Business Wire)
"Quantum-Si is leading the next generation of real-world meaningful sequencing," said Dr. Aris Persidis, Biovista's Co-Founder and President. "We are excited to see deep sequencing and insight generation now available in one integrated platform," he concluded.
(Source- Business Wire)
About Quantum-Si
Quantum-Si, The Protein Sequencing CompanyTM, is dedicated to revolutionizing the rapidly expanding field of proteomics. It provides the first-of-its-kind, end-to-end, universal single-molecule detection solutions, allowing to build, experiment, and discover on its platform regardless of their existing products. In addition, its proprietary Time Domain Sequencing technology eliminates the reliance on color as an identification method, a barrier for any application outside of genomics, where only four colors are required.
Read More
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
ImmunoGen, Inc. | March 02, 2023
On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing.
After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercialize conditioning agents using ImmunoGen's technology for that target. ImmunoGen will hol full rights to the ADC technology for any targets not covered by the Vertex license.
Vertex will pay an upfront payment of $15 million as part of the agreement. In addition, ImmunoGen is eligible to receive up to $337 million in option exercise fees, development, and commercial milestone payments for each target. ImmunoGen will also receive tiered royalties as a percentage of worldwide commercial sales of licensed targeted conditioning agents by Vertex. Vertex will be responsible for all research, development, and commercialization costs.
ImmunoGen's Executive Vice President, Research, Development, and Medical Affairs, Michael Vasconcelles, MD, commented, "Given Vertex's extensive experience discovering and developing transformative medicines for patients with serious diseases, we are thrilled they have chosen to explore ImmunoGen's technology to develop ADCs for transplant conditioning in connection with gene editing." He further emphasized, "This agreement reflects our continued innovation in the ADC space and demonstrates the value of our technology platform and related intellectual property."
(Source – Business Wire)
About ImmunoGen, Inc.
ImmunoGen is dedicated to improving the lives of people with cancer by developing precise, targeted cancer therapies. Its lead product candidate is a first-in-class ADC called mirvetuximab soravtansine, which targets folate receptor alpha (FRα) and is being studied in multiple ovarian cancer trials. The company's second program, IMGN632, is a CD123-targeting ADC being studied for the treatment of BPDCN and AML. ImmunoGen is also developing two earlier-stage assets: IMGC936, an ADAM9-targeting ADC co-developed with MacroGenics, and IMGN151, a next-generation anti-folate receptor alpha ADC. The company aims to keep cancer from disrupting people's lives and get them back to living today, tomorrow, and beyond.
Read More
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Caris Life Sciences | March 09, 2023
Caris Life Sciences®, a leading molecular science and technology firm and Incyte Corporation have recently announced a strategic research partnership to advance precision medicine approaches for Incyte's oncology pipeline.
Caris' innovative technology integrates data from whole exome sequencing, protein analysis, whole transcriptome sequencing and proprietary AI models and signatures to enhance patient outcomes through personalized medicine development. The partnership will initially apply Caris' data and analytics tools, comprehensive molecular liquid and tissue profiling services, and clinical trial enrollment program capabilities spans two therapeutic programs, with the option to expand to four total programs.
Incyte will use Caris' data insights and analytics capabilities to uncover novel biomarkers and enhance clinical positioning strategies for its oncology initiatives. Patients enrolling in Incyte-led clinical trials will be subjected to longitudinal testing with Caris' comprehensive tissue and liquid molecular profiling tests for drug candidates developed as part of the agreement. Incyte will also use Caris' biomarker-driven patient selection for clinical trials, with the possibility of collaborating on creating companion diagnostics for the partnership's programs.
Caris Life Sciences President and Chief Scientific Officer David Spetzler, MS, Ph.D., MBA, commented, "This partnership with Incyte will leverage Caris' leading molecular science and technology solutions to support Incyte's oncology research and development efforts." He further emphasized, "The aggregate strength of our platform, which provides patient level DNA and RNA data both in tissue and blood, may help to better identify and predict patient response to therapy, which in turn may accelerate clinical trial enrollment, optimize clinical positioning and potentially enhance technical and regulatory success."
(Source – PR Newswire)
About Caris Life Sciences
Caris Life Sciences® is a leading molecular science firm that utilizes advanced technologies to revolutionize healthcare. Its suite of molecular profiling offerings, which assess RNA, DNA and proteins, enables patients, researchers and physicians to improve outcomes and save lives by revealing a molecular blueprint. Additionally, it is advancing precision medicine through the use of advanced AI and machine learning algorithms by utilizing its proprietary analytics engine, DEAN™, to develop a better understanding of the molecular mechanisms of cancer. This information helps physicians to better identify and predict patient response to therapy and supports researchers and biopharmaceutical companies in research development, clinical trials, and target identification. With headquarters in Irving, Texas, the company has offices in several locations worldwide, providing services throughout the US, Europe, Asia, and other international markets.
Read More